Citations

Clear

590 citation(s) found for "Ho, Ben".

Prognostic impact of genetic variation in steroidogenic enzymes in advanced stage prostate cancer.
Zhang, Ben Yiming, Costello, Brian A. , Kohli, Manish , Kohli, Manish , Binder, Moritz , Quevedo, Fernando

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e16605-e16605

10.1200/jco.2016.34.15_suppl.e16605 Get It

Association of CYP17A1 single nucleotide polymorphism (SNP) with response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).
Zhang, Ben Yiming, Costello, Brian A. , Binder, Moritz , Quevedo, Fernando , Kohli, Manish

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e16603-e16603

10.1200/jco.2016.34.15_suppl.e16603 Get It

Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors.
Eroglu, Zeynep , Algazi, Alain P. , Johnson, Douglas B. , Liniker, Elizabeth, Kong, Ben L. , Sosman, Jeffrey A. , Scolyer, Richard A. , Postow, Michael A. , Carlino, Matteo S. , Hwu, Wen‐Jen , Long, Georgina V. , Long, Georgina V , Hu‐Lieskovan, Siwen , Zaretsky, Jesse Meir , Kim, Dae Won , Munhoz, Rodrigo Ramella , Rapisuwon, Suthee , Chmielowski, Bartosz , Joseph, Richard W. , Ribas, Antoni

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 9558-9558

10.1200/jco.2017.35.15_suppl.9558 Get It

9558 Background: Desmoplastic melanoma (DM) is a rare subtype of melanoma characterized by a dense fibrous stroma, resistance to chemotherapy and no actionable driver mutation for targeted therapy. We investigated the efficacy of PD-1/L1 inhibitors and correlation with genetic landscape and tumor immune microenvironment in DM. Methods: Retrospective analysis of 1054 pts with melanoma treated with anti-PD-1/L1, resulting in 57 pts with unresectable or metastatic DM. Available baseline biopsies were analysed by digital quantitative immunohistochemistry (IHC) for CD8 and PD-L1 and by whole exome sequencing (WES), compared to available tissue from non-DM pts treated with anti-PD1/L1 at UCLA. Results: At a median follow up of 20 mo, 40 pts (70%, 95% CI 57-82) had an objective response by RECIST 1.1 criteria, including 18 (45%) CRs with no relapse observed to date. Responses were similar in DM subsets (23 pure, 29 mixed and 5 indeterminate). Kaplan-Meier estimated 1-year and 2-year overall survival were 85% (95% CI 78-98) and 74% (95% CI 64-89). WES revealed a median of 1282 (interquartile range 517-1692) non-synonymous somatic mutations per tumor in DM tumors (n = 17), significantly higher (p = 0.02) than the median of 462 (interquartile range 230-1150) in non-DM (n = 23). Mutations in NF-1 were the most common (13/17) followed by loss-of-function TP53 and ARID2, and > 82% of single nucleotide mutations were UV damage signatures. IHC analysis from 19 DM and 13 non-DM revealed a strikingly higher percentage of PD-L1 positive cells in the tumor parenchyma in DM (p = 0.04), highly associated with CD8 density and PD-L1 expression in the tumor invasive margins, indicating an active adaptive immune response. No genetic mechanisms known to cause constitutive PD-L1 expression were detected in these samples. Conclusions: Patients with advanced DM derive significant clinical benefit from PD-1/L1 inhibitors, likely related to the high mutational burden and a highly active adaptive immune response as the main mechanism of immune escape prior to therapy. Our results challenge the general conception that dense fibrous stroma around the malignant cells interferes with immune cell infiltration and efficacy of immunotherapy.
B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): An open-label, randomized phase II/III trial.
Nowakowski, Grzegorz S. , Molina, Lysianne, Kopečková, Kateřina , Laribi, Kamel , García, R. del Campo, Coiffier, Bertrand , Rummel, Mathias , Rosenwald, Andreas , Winderlich, Mark, Korolkiewicz, Roman , Belada, David , Laribi, Kamel , Jurczak, Wojciech , Heß, Georg , Zinzani, Pier Luigi

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: TPS7571-TPS7571

10.1200/jco.2017.35.15_suppl.tps7571 Get It

TPS7571 Background: Patients ineligible for stem cell transplantation (SCT) or who relapse after SCT, and those who fail to respond to second-line or salvage chemotherapy, represent an unmet medical need for which new therapeutic strategies are required. MOR208 is a novel Fc-enhanced, humanized, monoclonal antibody directed against CD19. Significant single-agent activity of MOR208 in patients with R-R DLBCL (Jurczak et al., J Clin Oncol 34, 2016 [suppl; abstr 7545]) and enhancement of MOR208-mediated cytotoxicity by BEN in preclinical studies, provide a strong rationale to study MOR208 + BEN in patients with R-R DLBCL. Methods: B-MIND is a randomized (1:1), two-arm, multicenter, open-label, adaptive design, phase II/III study of MOR208 + BEN vs RTX + BEN in adult patients with histologically confirmed DLBCL who have relapsed after or are refractory to 1 to 3 prior lines of therapy and who are not candidates for high-dose chemotherapy and autologous SCT. At least 1 prior therapy line must have included a CD20-targeted therapy. Other key inclusion criteria: age ≥18 years; measurable disease; availability of tumor tissue for central pathology review; ECOG 0–2, and adequate major organ systems function. Key exclusion criteria: primary refractory DLBCL; central nervous system involvement, and known double/triple hit DLBCL genetics. The safety of the combination will be assessed in an initial phase II evaluation. Treatment will comprise 6 cycles of MOR208 (12 mg/kg IV) + BEN (90 mg/m2 IV) or RTX 375 mg/m2 IV + BEN. Patients achieving a response after cycle 6 will continue to receive antibody treatment for up to 18 additional cycles. Primary endpoint: progression-free survival (PFS); secondary endpoints include: best overall response, overall survival, safety, quality of life, immunogenicity and pharmacokinetics. Enrollment of 330 patients is anticipated in Europe, US and Asia-Pacific countries. Fourteen patients have been randomized to date. Clinical trial information: NCT02763319.
Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.
Leiba, Merav , Suzuki, Kenshi , Kumar, Shaji , Lentzsch, Suzanne , Hájek, Roman , Sonneveld, Pieter , Wu, Kaida, Qin, Xiang , Soong, David, Qi, Ming , Schecter, Jordan M. , Hajek, Roman , Weisel, Katja C , Miguel, Jesús F. San , Cook, Gordon , Cavo, Michèle , Avet‐Loiseau, Hervé , Quach, Hang , Hungria, Vânia , Chiu, Christopher, Dimopoulos, Meletios Α.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 8006-8006

10.1200/jco.2017.35.15_suppl.8006 Get It

8006 Background: In 2 randomized phase 3 trials of RRMM patients (pts), DRd (POLLUX) or DVd (CASTOR) significantly improved PFS and deepened responses compared with Rd or Vd alone, respectively. The novel mechanism of action of daratumumab (D) may improve the poor prognosis associated with high-risk cytogenetic abnormalities in RRMM. Therefore, we examined the efficacy of DRd and DVd among RRMM pts with standard (std) or high cytogenetic risk status. Methods: Bone marrow aspirates were collected at screening and assessed centrally via next generation sequencing (NGS). Pts with high-risk cytogenetics included those who had ≥1 of the following abnormalities: t(4;14), t(14;16), or del17p; std-risk pts were defined as those confirmed negative for these abnormalities. Efficacy analyses included PFS and ORR. Results: Samples from 311/569 pts in POLLUX and 353/498 pts in CASTOR were assessed via NGS. In POLLUX, the median duration of follow-up was 17.3 months. Significantly longer median PFS and numerically higher ORR were observed with DRd vs Rd among high-risk patients, and significant improvements in these outcomes were observed in std-risk patients (Table). In CASTOR, the median duration of follow-up was 13.0 months. Significantly longer median PFS and higher ORR were observed with DVd vs Vd among both high- and std-risk pts (Table). Concordance rates for t(4;14), t(14;16), and del17p were high (88%-98%) between NGS and FISH. Updated data, including subgroup analyses, will be presented. Conclusions: In RRMM pts, the addition of D to standard-of-care regimens improved outcomes regardless of cytogenetic risk status. Targeting CD38 by combining D with Rd or Vd appears to improve the poor outcomes associated with high-risk cytogenetic status. See table. Clinical trial information: NCT02136134 and NCT02076009. [Table: see text]
A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).
Attia, Steven , Sankhala, Kamalesh K. , Riedel, Richard F. , Conry, Robert M. , Fritchie, Karen , Seon, Ben K. , Alvarez, Delia, Adams, Bonne J., Shazer, Ronald , Theuer, Charles P. , Maki, Robert G. , Maki, Robert G , Riedel, Richard F , Robinson, Steven I. , Boland, Patrick M. , Barve, Minal

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 11016-11016

10.1200/jco.2016.34.15_suppl.11016 Get It

A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies.
Vidula, Neelima , Goga, Andrei , Hwang, Jimmy , Liu, Minetta C. , Nanda, Rita , Pohlmann, Paula R. , Storniolo, Anna Maria , Brufsky, Adam , Brufsky, Adam M , Park, Ben Ho , Abramson, Vandana G. , Rugo, Hope S. , Pohlmann, Paula

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS1113-TPS1113

10.1200/jco.2018.36.15_suppl.tps1113 Get It

4994Transcatheter versus surgical aortic valve replacement in patients with prior cardiac surgery in the randomized PARTNER 2A Trial
Chen, S, Redfors, Björn , Ben‐Yehuda, Ori , Crowley, Aaron , Greason, Kevin L. , Finn, Matthew , Vahl, Torsten , Thourani, Vinod H. , Suri, Rakesh M. , Svensson, Lars G. , Webb, John G. , Kodali, Susheel , Leon, M.B., Investigators, the PARTNER 2 Trial, Alu, Maria C. , Nazif, Tamim , Investigators, the PARTNER 2 Trial

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy566.4994 Get It

Age‐specific genome‐wide association study in glioblastoma identifies increased proportion of ‘lower grade glioma’‐like features associated with younger age
Ostrom, Quinn T. , Kinnersley, Ben , Armstrong, Georgina , Rice, Terri, McCoy, Lucie , Hansen, Helen M. , Bernstein, Jonine L. , Claus, Elizabeth B. , Eckel‐Passow, Jeanette E. , Johansen, Christoffer , Lai, Rose , Merrell, Ryan , Sadetzki, Siegal , Schildkraut, Joellen M. , Shete, Sanjay , Andersson, Ulrika , Rajaraman, Preetha , Linet, Martha S. , Wang, Zhaoming , Houlston, Richard S. , Jenkins, Robert B. , Wrensch, Margaret , Melin, Beatrice , Bondy, Melissa L. , Barnholtz‐Sloan, Jill S. , Houlston, Richard S , Barnholtz-Sloan, Jill S , Wang, Zhaoming , Armstrong, Georgina , Chen, Yanwen , Wiencke, John K. , Amos, Christopher I. , Il’yasova, Dora , Lachance, Daniel Honore , Olson, Sara H. , Rubin, Joshua B , Chanock, Stephen Jacob , Yeager, Meredith , Ostrom, Quinn T

Mayo Clinic

International Journal of Cancer | August 29, 2018 | Volume: 143 | Issue: 10 | Pages: 2359-2366

10.1002/ijc.31759 | PMID 30152087 Get It

Glioblastoma (GBM) is the most common malignant brain tumor in the United States. Incidence of GBM increases with age, and younger age‐at‐diagnosis is significantly associated with improved prognosis. While the relationship between candidate GBM risk SNPs and age‐at‐diagnosis has been explored, genome‐wide association studies (GWAS) have not previously been stratified by age. Potential age‐specific genetic effects were assessed in autosomal SNPs for GBM patients using data from four previous GWAS. Using age distribution tertiles (18–53, 54–64, 65+) datasets were analyzed using age‐stratified logistic regression to generate p values, odds ratios (OR), and 95% confidence intervals (95%CI), and then combined using meta‐analysis. There were 4,512 total GBM cases, and 10,582 controls used for analysis. Significant associations were detected at two previously identified SNPs in 7p11.2 (rs723527 [p54–63 = 1.50x10−9, OR54–63 = 1.28, 95%CI54–63 = 1.18–1.39; p64+ = 2.14x10−11, OR64+ = 1.32, 95%CI64+ = 1.21–1.43] and rs11979158 [p54–63 = 6.13x10−8, OR54–63 = 1.35, 95%CI54–63 = 1.21–1.50; p64+ = 2.18x10−10, OR64+ = 1.42, 95%CI64+ = 1.27–1.58]) but only in persons >54. There was also a significant association at the previously identified lower grade glioma (LGG) risk locus at 8q24.21 (rs55705857) in persons ages 18–53 (p18–53 = 9.30 × 10−11, OR18–53 = 1.76, 95%CI18–53 = 1.49–2.10). Within The Cancer Genome Atlas (TCGA) there was higher prevalence of ‘LGG’‐like tumor characteristics in GBM samples in those 18–53, with IDH1/2 mutation frequency of 15%, as compared to 2.1% [54–63] and 0.8% [64+] (p = 0.0005). Age‐specific differences in cancer susceptibility can provide important clues to etiology. The association of a SNP known to confer risk for IDH1/2 mutant glioma and higher prevalence of IDH1/2 mutation within younger individuals 18–53 suggests that more younger individuals may present initially with ‘secondary glioblastoma.’
Concerns over Airway Pressure Release Ventilation Management in Children with Acute Respiratory Distress Syndrome
Daxon, Ben, Daxon, Benjamin T.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 27, 2018 | Volume: 198 | Issue: 11 | Pages: 1458-1459

10.1164/rccm.201806-1164le | PMID 30148966 Get It